Switch to:

Amplia Therapeutics Cash-to-Debt

: No Debt (As of Sep. 2019)
View and export this data going back to 2015. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Amplia Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2019 was No Debt.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Amplia Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

OTCPK:INNMF' s Cash-to-Debt Range Over the Past 10 Years
Min: 112.82   Med: No Debt   Max: No Debt
Current: No Debt

112.82
No Debt

During the past 8 years, Amplia Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 112.82. And the median was No Debt.

OTCPK:INNMF's Cash-to-Debt is ranked higher than
100% of the 1246 Companies
in the Biotechnology industry.

( Industry Median: 8.35 vs. OTCPK:INNMF: No Debt )

Amplia Therapeutics Cash-to-Debt Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Amplia Therapeutics Annual Data
Jun13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt 112.82 No Debt

Amplia Therapeutics Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt 112.82 No Debt No Debt

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Amplia Therapeutics Cash-to-Debt Distribution

* The bar in red indicates where Amplia Therapeutics's Cash-to-Debt falls into.



Amplia Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Amplia Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Mar. 2020 is calculated as:

Amplia Therapeutics had no debt.

Amplia Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

Amplia Therapeutics had no debt.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Amplia Therapeutics  (OTCPK:INNMF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Amplia Therapeutics Cash-to-Debt Related Terms


Amplia Therapeutics Cash-to-Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)